Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cara Therapeutics (NQ: CARA )

3.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cara Therapeutics

Cara Therapeutics to Present at the Jefferies Healthcare Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in... 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Reports First Quarter 2023 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment 
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Reports Third Quarter 2022 Financial Results
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Present at Upcoming Investor Conferences
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
From Cara Therapeutics, Inc.
Via GlobeNewswire
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
From Cara Therapeutics, Inc.
Via GlobeNewswire
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
From Vifor Pharma Group
Via Business Wire
Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels
Via FinancialNewsMedia
Topics Cannabis Economy
Exposures COVID-19 Cannabis Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.